Kiniksa Reports Results of Mavrilimumab in P-III Trial for the Treatment of COVID-19-Related ARDS
Shots:
- The company reported the results from the P-III portion of the P-II/III trial to evaluate mavrilimumab (10/6mg/kg, IV) vs PBO in a ratio (1:1:1) in 582 patients with COVID-19-related ARDS
- The trial failed to meet its primary efficacy 1EPs of a proportion of patients alive and free of mechanical ventilation @29Day. Additionally, the company focuses on the Arcalyst franchise including the commercial execution in recurrent pericarditis along with the development of vixarelimab and KPL-404
- Mavrilimumab is an investigational fully human mAb that targets GM-CSFRα & is currently being evaluated in GCA. The therapy has received ODD from the US FDA for GCA in 2020
Ref: Kiniska | Image: Kiniksa
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com